The Technical Analyst
Atreca Inc [BCEL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Atreca Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.18% $0.0770
America/New_York / 19 apr 2024 @ 15:42
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.05 mill |
| EPS: | -2.50 |
| P/E: | -0.0300 |
| Earnings Date: | Apr 19, 2024 |
| SharesOutstanding: | 39.62 mill |
| Avg Daily Volume: | 1.247 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0300 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0300 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0500 - 0.104 ( +/- 35.06%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Orwin John A | Buy | 1 | Series A Junior Preferred Stock |
| 2024-04-01 | Serafini Tito | Sell | 20 788 | Class A Common Stock |
| 2023-09-01 | Orwin John A | Sell | 22 951 | Class A Common Stock |
| 2023-09-01 | Serafini Tito | Sell | 8 393 | Class A Common Stock |
| 2023-09-01 | Courtney Phillips | Sell | 7 061 | Class A Common Stock |
| INSIDER POWER |
|---|
| 26.50 |
| Last 95 transactions |
| Buy: 4 455 146 | Sell: 2 042 595 |
Forecast:
16:00 - $0.0770
Live Trading Signals (every 1 min)
Forecast
1: 15:52 - $0.0770
Forecast 2: 16:00 - $0.0770
Forecast 3: 16:00 - $0.0770
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0770 (1.18% ) |
| Volume | 0.0140 mill |
| Avg. Vol. | 1.247 mill |
| % of Avg. Vol | 1.126 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BCEL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:29 | buy | $0.268 | N/A | Active |
|---|
BCEL
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
Last 10 Buy Signals
Latest Press Releases
2023-12-26 12:53:00 - Press Release
Bcel Stock Alert: Halper Sadeh Llc Is Investigating Atreca, Inc.
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether atreca, inc.'s (nasdaq: bcel) definitive asset purchase agreement with immunome, inc. to sell a collection of antibody-related assets and materials is fair to atreca shareholders. under the terms of the agreement, immunome would pay atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones. on behalf of atreca shareholders, h.
2023-12-26 08:30:00 - Press Release
Immunome To Acquire Antibody-related Assets And Materials From Atreca
Seattle & exton, pa.--(business wire)--immunome, inc. (nasdaq: imnm), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with atreca, inc. (nasdaq: bcel) to acquire a collection of antibody-related assets and materials. “we believe that novel and underexplored targets will drive the next generation of transformative adcs. these antibody-related assets will expand our.
2023-12-26 08:30:00 - Press Release
Atreca Announces Asset Purchase Agreement For Sale Of Antibody-related Assets And Materials To Immunome
Campbell, calif., dec. 26, 2023 (globe newswire) -- atreca, inc. (“atreca”) (nasdaq: bcel), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it entered into a definitive asset purchase agreement with immunome, inc. (nasdaq: imnm) to sell a collection of antibody-related assets and materials. under the terms of the agreement, immunome would pay atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones.
2023-11-14 16:30:00 - Press Release
Atreca Reports Third Quarter 2023 Financial Results And Announces Further Reorganization To Support Exploration Of Strategic Alternatives
San carlos, calif., nov. 14, 2023 (globe newswire) -- atreca, inc. (atreca) (nasdaq: bcel), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended september 30, 2023, and announced that the company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives.
2023-09-21 08:00:00 - Press Release
Atreca Announces Agreement To Terminate Lease And Departure Of Chief Financial Officer Herb Cross
San carlos, calif., sept. 21, 2023 (globe newswire) -- atreca, inc. (atreca) (nasdaq: bcel), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that, as part of its ongoing efforts to lower operating expenses, the company has entered into an agreement to terminate its lease agreement pertaining to the company's headquarters in san carlos, ca, which represented approximately $13 million of annual expenditures. in addition, herb cross, chief financial officer, will depart the company on september 22, 2023, to pursue an external opportunity. mr. cross will continue to support the company as a consultant through the first quarter of 2024...
Latest News
2024-01-11 08:02:09 - InvestorPlace
Why Is Atreca (BCEL) Stock Up 85% Today?
Atreca (NASDAQ: BCEL ) stock is rising higher on Thursday following news of a major stake in the clinical-stage biopharmaceutical company from an investment advisor. According to a filing with the Securities and Exchange Commission (SEC), Baker Bros.
2023-08-14 12:24:24 - Zacks Investment Research
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.
2023-07-13 13:03:43 - InvestorPlace
3 Penny Stocks to Catapult You Into the Millionaires' Club
Tech companies in certain high-growth sectors like semiconductors, AI, and cloud predominantly drove this year's bull market. But while these giants made headlines, many penny stocks continued trading at bargain prices.
2023-03-29 20:36:02 - Seeking Alpha
Atreca, Inc. (BCEL) Q4 2022 Earnings Call Transcript
Atreca, Inc. (NASDAQ:BCEL ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Alex Gray - Head of Investor Relations John Orwin - CEO Tito Serafini - Chief Strategy Officer and Founder Philippe Bishop - Chief Medical Officer Stephen Gould - Chief Scientific Officer Herb Cross - Chief Financial Officer Conference Call Participants Divya Rao - Cowen Roger Song - Jefferies John Newman - Canaccord Tony Butler - EF Hutton Stephen Willey - Stifel Kemp Dolliver - Brookline Capital Operator Thank you for standing by. Welcome to the Atreca's Fourth Quarter and Year End 2022 Earnings Call.
2023-03-23 17:00:00 - GlobeNewsWire
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101 Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101
2023-02-14 09:47:18 - InvestorPlace
Why Is Atreca (BCEL) Stock Up Today?
Atreca (NASDAQ: BCEL ) stock is getting a boost on Tuesday as the company continues a recent rally connected to insider buying. On Monday, shares of BCEL stock jumped nearly 14% after a series of filings with the U.S. Securities and Exchange Commission (SEC).
2023-02-01 11:35:13 - Seeking Alpha
Atreca Locks In A Catalyst In The Oncology Space
BCEL is set to produce additional data from a phase 1b trial of its antibody ATRC-101 in multiple solid tumor types. Based on previous data, BCEL has refined the patients it enrolls in the trial, which could improve the strength of the results it produces.
2022-11-07 16:30:00 - GlobeNewsWire
Atreca to Present at Upcoming Investor Conferences
SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming conferences:
2022-09-09 16:05:00 - GlobeNewsWire
Atreca to Present at Upcoming Investor Conferences
SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming investor conferences:
2022-08-02 16:30:00 - GlobeNewsWire
Atreca to Present at Upcoming Investor Conferences
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate at the following upcoming investor conferences: